Literature DB >> 32898694

Inhibitory effect of 5-FU loaded ultrasound microbubbles on tumor growth and angiogenesis.

Yang He1, Yue Zhang1, Hai-Ying Qin1, Dong-Yue Gu1, Xiao Lu1, Jin-Xi Hu1, Wei-Liang Ye2, Guang-Bin He3.   

Abstract

The anti-neovascularization treatment is one of the effective strategies for tumor molecular target therapy. At present, the target and effect of the anti-neovascularization treatment is limited, and it is urgent to establish a new vascular targeting strategy to effectively treat tumors. In this work, we used high intensity focused ultrasound (HIFU) combined with targeted microbubbles to establish a molecular targeted ultrasound response microbubble for neovascular cells. Furthermore, the effects of drug loaded microbubbles on neovascularization and tumor cells were studied. The tumor vascular targeted and ultrasound-responsive microbubbles of 5-FU@DLL4-MBs were prepared by the thin-film dispersion method. The size and zeta potential of 5-FU@DLL4-MBs was about 1248 nm and -9.1 mV. 5-FU@DLL4-MBs released 5-FU showed an ultrasound-responsive manner, and had better vascular-targeting ability. Furthermore, the 5-FU@DLL4-MBs showed the strongest cytotoxic effect on HUVECs or HepG-2 cells and can be effectively internalized into the HUVECs cells. Thus, 5-FU@DLL4-MBs combined with HIFU can be considered as a potential method for antitumor angiogenesis in the future.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-tumor angiogenesis; Hepatic carcinoma; High intensity focused ultrasound (HIFU); Microbubbles (Mbs); Ultrasound-responsive

Mesh:

Substances:

Year:  2020        PMID: 32898694     DOI: 10.1016/j.bmcl.2020.127534

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

1.  Theranostic Microbubbles with Homogeneous Ligand Distribution for Higher Binding Efficacy.

Authors:  Simone A G Langeveld; Bram Meijlink; Inés Beekers; Mark Olthof; Antonius F W van der Steen; Nico de Jong; Klazina Kooiman
Journal:  Pharmaceutics       Date:  2022-01-28       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.